Adjuvant vinorelbine plus cisplatin versus vinorelbine plus cisplatin plus Endostar [endostatin] in patients with completely resected stage IB-IIIA non-small cell lung cancer (phase III study, randomized, open, multi-center)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 27 Sep 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Endostatin (Primary) ; Cisplatin; Vinorelbine
Indications Non-small cell lung cancer
Focus Therapeutic Use

Most Recent Events

05 Jun 2012 Preliminary results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
07 Jul 2011 Results presented at the 14th World Conference on Lung Cancer.
08 Jun 2010 Interim results from 545 patients presented at 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight